Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 8-Chlorotheophylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Chlorotheophylline SCHEMBL5719335 | 0.98 | POLB (0.55) | POLBHSD17B10ALDH1A1CYP3A4CASP1 | |
| SCHEMBL3181178 | 0.82 | ADORA2A (0.54) | POLBCYP3A4CYP1A2ADORA2AADORA2B | |
| SCHEMBL237859 | 0.80 | SMN1; SMN2 (0.60) | POLBHSD17B10ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL3175170 | 0.80 | PDE4A (0.55) | ADORA2AADORA2B | |
| SCHEMBL461786 | 0.79 | PDE2A (0.62) | POLBHSD17B10ALDH1A1CYP3A4CASP1 | |
| SCHEMBL1808708 | 0.79 | PDE1A (0.48) | HSD17B10ALDH1A1CYP3A4CYP1A2LMNA | |
| Hydrazine SCHEMBL9281750 | 0.78 | SMN1; SMN2 (0.58) | POLBHSD17B10ALDH1A1CYP1A2LMNA | |
| SCHEMBL3175131 | 0.78 | PDE4A (0.57) | CYP1A2ADORA2A | |
| Pamabrom SCHEMBL237881 | 0.78 | POLB (0.61) | POLBHSD17B10ALDH1A1CYP3A4CASP1 | |
| SCHEMBL20783386 | 0.78 | POLB (0.57) | POLBHSD17B10ALDH1A1CYP3A4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250376444-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CYTOKINETICS INC (US) | 2025-12-11 | — | — | US | claimed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORP (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024192323-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2008102367-A1 | PROCESS FOR PREPARATION OF PYRAZOLE DERIVATIVES | SHAH DARMESH MAHENDRABHAI (IN) | 2008-08-28 | — | — | WO | claimed |
| US-20050065335-A1 | Polynucleotide intercalator interceptors and inhibitors | MATERIALS EVOLUTION AND DEVELOPMENT USA, INC | 2005-03-24 | — | — | US | claimed |
| CN-1596254-A | Process for the prereparation of compositions having an increased amount of pharmaceutically active salts of rotamers | SCHERING CORP (US) | 2005-03-16 | — | — | CN | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| EP-1318796-A2 | POLYNUCLEOTIDE INTERCALATOR INTERCEPTORS AND INHIBITORS | Lyles, Mark B. (US) | 2003-06-18 | — | — | EP | claimed |
| WO-2002045707-A2 | POLYNUCLEOTIDE INTERCALATOR INTERCEPTORS AND INHIBITORS | LYLES MARK B (US) | 2002-06-13 | — | — | WO | claimed |
| US-6372799-B1 | ANTIALLERGENS OR CHOLINERGIC DISORDERS | BRIDGE PHARMA, INC. | 2002-04-16 | — | — | US | claimed |
| WO-2000008928-A1 | NON-SEDATING DIPHENHYDRAMINE METABOLITES | BRIDGE PHARMA, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| US-4164577-A | BACTERICIDES | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1979-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | HRH1 620/4885POLB 310/4885HSD17B10 848/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | HRH1 282/4885POLB 3981/4885HSD17B10 3013/4885 |
| US-20250376444-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | SI, MLN, MLNR | HRH1 493/4885POLB 2422/4885HSD17B10 3993/4885 |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | PDE12, TBXA2R, PDE6G | HRH1 766/4885POLB 1946/4885HSD17B10 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.